Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Moderna's CEO Stephan Bancel comments on mRNA cancer vaccine

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 11, 2023 12:59pm

159 Views

Post# 35216160

RE:RE:Moderna's CEO Stephan Bancel comments on mRNA cancer vaccine

Now both Moderna and BioNTech have announced that they are diverting significant resources towards the development of their oncology programs, in the areas that ONCY has developed pelareorep which now happens to be "Phase 3 ready" and that can be translated into "accelerated approval ready".

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market